Clin2
NCT07246278Possibly a fitRecruiting

Celecoxib for Parkinson's: A new way to treat symptoms

Parkinson Disease

Treatments studied

Part of Brain & nervous system clinical trials.

This trial tests if adding celecoxib, an anti-inflammatory drug, to standard Parkinson's treatment can help improve symptoms. If you have Parkinson's disease and are at least 18, this study might be an option for you.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
80 people
Ages
50 years to 80 years
Study type
Interventional

Who can take part

  • You are 18 years old or older.
  • You have been diagnosed with Parkinson's disease.
  • You are not pregnant, breastfeeding, or planning to become pregnant.
  • You do not have serious liver or kidney problems.
  • You are not allergic to celecoxib, sulfonamides, or similar drugs.
  • You do not use other anti-inflammatory drugs or have a history of alcohol or drug abuse.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07370532Recruiting· Phase 2
Etoricoxib for Parkinson's disease

This study tests if etoricoxib, an anti-inflammatory drug, can help people with Parkinson's disease. You may join if you have a confirmed diagnosis and are not using other anti-inflammatory drugs.

Al Mansurah
NCT06785298Recruiting· Phase 2/Phase 3
Fexofenadine as add-on treatment for Parkinson's disease

This trial tests whether adding fexofenadine, a common allergy medicine, to your current Parkinson's treatment can help improve symptoms. It's for people aged 50 or older who are already on dopamine replacement therapy.

Tanta
NCT07005180Recruiting· Phase 2
Carbon monoxide gas for Parkinson's disease

This trial tests if a low dose of carbon monoxide (HBI-002) is safe and helpful for people with Parkinson's disease. It requires specific health criteria and stable Parkinson's medication.

Fountain Valley, California
NCT06629389Recruiting· Phase 2
Cannabidiol (Kanbis) for Parkinson's symptoms

This trial tests whether cannabidiol (CBD) can help with Parkinson's disease symptoms. Researchers want to see if it's safe and effective for people with mild to moderate Parkinson's who are already on stable medications.

Mendoza, Mendoza Province
NCT06612593Not yet recruiting· Phase 2
Cilostazol for Parkinson's disease with dyskinesia

This trial tests whether the drug cilostazol can help people with Parkinson's disease who have involuntary movements (dyskinesia) caused by their levodopa treatment. You may join if you have had Parkinson's for at least 5 years, take stable doses of levodopa/carbidopa, and have dyskinesia.

Cairo
NCT05576818Recruiting· Phase 3
Synbiotic add-on for people with Parkinson’s disease

This trial tests whether adding a synbiotic (a mix of probiotics and prebiotics) along with standard Parkinson’s medicines can improve symptoms or health outcomes. It’s mainly for adults with Parkinson’s disease at earlier to mid-stages who take dopamine replacement therapy.

Tanta, El Gharbia

Hear when a new Parkinson Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.